October 11, 2022 10:54 AM EDT

Rigel steps back from sNDA filing plans for bleeding disorder drug; NMD gives first look into myasthenia gravis program

Lei Lei Wu

News Reporter

In June, Rigel reported a Phase III fail for its only approved drug, fostamatinib, in warm autoimmune hemolytic anemia, or wAIHA for short, an autoimmune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rigel steps back from sNDA filing plans for bleeding disorder drug; NMD gives first look into myasthenia gravis program

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

GLP-1s can cut the risk of Alzheimer’s. What does that mean for Novo Nordisk?

China's biotech boom is threatening US drugmakers' dominance

J&J’s Spravato hit $1B in revenue in 2024

US withdrawal from WHO could jeopardize information sharing

Inhibrx’s early colorectal cancer data clouded by patient death

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Rigel steps back from sN­DA fil­ing plans for bleed­ing dis­or­der drug; NMD gives first look in­to myas­the­nia gravis pro­gram

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Rigel steps back from sNDA filing plans for bleeding disorder drug; NMD gives first look into myasthenia gravis program